Attention Investors
Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000.    |   Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors."     |    KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."     |    ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
 ««+1  ««-1
 
 
Lupin LtdIndustry : Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code:500257NSE Symbol: LUPINP/E(TTM):18.8
ISIN Demat:INE326A01037Div & Yield %:0.55EPS(TTM):116.75
Book Value(Rs):595.7690006Market Cap ( Cr.):100286.19Face Value(Rs):2
    Change Company 
Date Headline
02-Feb-26 Lupin announces strategic collaboration with TB Alliance
02-Feb-26 Lupin launches Dasatinib Tablets in U.S. market
02-Feb-26 Lupin joins hands with TB Alliance to accelerate clinical development of Telacebec
29-Jan-26 Lupin to discuss results
27-Jan-26 Lupin allots 1.69 lakh equity shares under ESOP
23-Jan-26 Lupin receives S&P Global ESG score of 91 in 2025
21-Jan-26 Lupin signs licensing and supply agreement with Galenicum Health
30-Dec-25 Lupin enters licensing agreement with Gan & Lee Pharmaceuticals
30-Dec-25 Lupin signs exclusive licensing deal with Gan & Lee for novel GLP-1 receptor agonist
17-Dec-25 Lupin gets EIR from US FDA for Nagpur-based injectable facility
<< < 1 2 3 4   > >>